HUMA Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.625

Open

0.589

VWAP

0.60

Vol

7.10M

Mkt Cap

134.70M

Low

0.560

Amount

4.24M

EV/EBITDA(TTM)

--

Total Shares

222.02M

EV

141.90M

EV/OCF(TTM)

--

P/S(TTM)

44.58

Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.

Show More

Events Timeline

(ET)

2026-03-31

08:50:00

Significant Increases in Indicative Borrow Rates for Liquid Options

2026-03-27 (ET)

2026-03-27

09:00:00

Stock Futures Modestly Lower as Energy Prices Rise

2026-03-27

07:20:00

Humacyte Q4 Revenue $467K, Below Consensus

2026-03-19 (ET)

2026-03-19

08:40:00

Humacyte Secures $1.475M Purchase Commitment

2026-03-19

08:40:00

Humacyte Signs Agreement to Sell 25 Million Shares

2026-03-17 (ET)

2026-03-17

08:20:00

Humacyte Submits Symvess Application to Israel Ministry of Health

2026-02-20 (ET)

2026-02-20

08:50:00

Liquid Option Borrow Rates Increase

News

NASDAQ.COM

03-27NASDAQ.COM

Humacyte Reports 2025 Financial Results and Pipeline Updates

seekingalpha

03-27seekingalpha

Humacyte Q4 Earnings Report Analysis

Newsfilter

03-27Newsfilter

Humacyte Reports Q4 2025 Financial Results and Business Update

moomoo

Humacyte Reports Q4 Net Income of -$24.804 Million, Exceeding IBES Estimate of -$23.3 Million

seekingalpha

03-26seekingalpha

Humacyte to Announce Q4 Earnings on March 27

Yahoo Finance

03-20Yahoo Finance

Humacyte Submits Marketing Authorization Application in Israel

4 Analyst Rating

Wall Street analysts forecast HUMA stock price to rise

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

3.00

Averages

5.88

High

11.00

Current: 0.000

Low

3.00

Averages

5.88

High

11.00

Benchmark

Buy -> Speculative Buy

downgrade

$10 -> $1

AI Analysis

2026-03-31

New

Reason

Benchmark

Price Target

$10 -> $1

AI Analysis

2026-03-31

New

downgrade

Buy -> Speculative Buy

Reason

Benchmark downgraded Humacyte to Speculative Buy from Buy with a price target of $1, down from $10, after updating the firm's model for Q4 results. The firm's change in rating to a Speculative Buy "is not a downgrade per se, but better reflects the higher risk profile associated with the shares," the analyst tells investors. The rate of uptake in 2025 was "not what we hoped for," adds the analyst, who is lowering the firm's 2026 revenue estimate to $13.8M from $21.8M.

Piper Sandler

Allison Bratzel

Neutral

downgrade

$3 -> $1

2026-03-30

New

Reason

Piper Sandler

Allison Bratzel

Price Target

$3 -> $1

2026-03-30

New

downgrade

Neutral

Reason

Piper Sandler analyst Allison Bratzel lowered the firm's price target on Humacyte to $1 from $3 and keeps a Neutral rating on the shares following Q4 earnings. The company reported more progress on VAC approvals, with the new, lower $17k price helping accelerate hospital orders by aligning more closely with comparable surgical products, but it's unclear to the firm how soon this will translate to significant demand.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for HUMA

Unlock Now

Valuation Metrics

The current forward P/E ratio for Humacyte Inc (HUMA.O) is -2.08, compared to its 5-year average forward P/E of -5.82. For a more detailed relative valuation and DCF analysis to assess Humacyte Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-5.82

Current PE

-2.08

Overvalued PE

-1.50

Undervalued PE

-10.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-3.23

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.69

Undervalued EV/EBITDA

-8.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

740.29

Current PS

9.86

Overvalued PS

2075.08

Undervalued PS

-594.51

Financials

AI Analysis

Annual

Quarterly

Whales Holding HUMA

Trading Trends

People Also Watch

Frequently Asked Questions

What is Humacyte Inc (HUMA) stock price today?

The current price of HUMA is 0.6067 USD — it has increased 5.57

What is Humacyte Inc (HUMA)'s business?

Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.

What is the price predicton of HUMA Stock?

Wall Street analysts forecast HUMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUMA is5.88 USD with a low forecast of 3.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Humacyte Inc (HUMA)'s revenue for the last quarter?

Humacyte Inc revenue for the last quarter amounts to 467.00K USD, decreased

What is Humacyte Inc (HUMA)'s earnings per share (EPS) for the last quarter?

Humacyte Inc. EPS for the last quarter amounts to -0.13 USD, decreased -18.75

How many employees does Humacyte Inc (HUMA). have?

Humacyte Inc (HUMA) has 184 emplpoyees as of April 01 2026.

What is Humacyte Inc (HUMA) market cap?

Today HUMA has the market capitalization of 134.70M USD.